Galectin Therapeutics INC (GALT) — 10-K Filings

All 10-K filings from Galectin Therapeutics INC. Browse 3 Annual Report reports with AI-powered summaries and risk analysis.

10-K Filings (3)

GALT's Belapectin Shows Promise in MASH Cirrhosis, Varices Reduced — Mar 31, 2026 Risk: high
GALECTIN THERAPEUTICS INC. (GALT) reported top-line results for its NAVIGATE Phase 2b/3 clinical trial in December 2024, evaluating belapectin for the preventio
Galectin Therapeutics Files 2024 10-K — Mar 31, 2025 Risk: medium
Galectin Therapeutics Inc. filed its 2024 10-K on March 31, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Pro Phar
Galectin Therapeutics Inc. Files 2023 Annual Report on Form 10-K — Mar 29, 2024 Risk: medium
GALECTIN THERAPEUTICS INC (GALT) filed a Annual Report (10-K) with the SEC on March 29, 2024. Galectin Therapeutics Inc. filed its 2023 Form 10-K on March 29, 2

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX